Literature DB >> 8778037

Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.

Y Z Jiang1, D Couriel, D A Mavroudis, P Lewalle, V Malkovska, N F Hensel, S Dermime, J Molldrem, A J Barrett.   

Abstract

Major histocompatibility complex (MHC) class I antigens on tumour cell surfaces have been shown to modulate target susceptibility to natural killer (NK) cell-mediated lysis in some, although not all, systems investigated. MHC class II expression may also affect NK cell function, but the mechanism by which MHC class II antigen regulates NK cell activity has not been fully examined. In this study we induced HLA-DR1 expression by gene transfection into the classic NK-sensitive K562 cell line to study the interaction of NK cells with MHC class II molecules and the effect of brefeldin-A (BFA), an endogenous antigen-processing pathway blocker, on NK-target cell interaction. We demonstrated that the expression of HLA-DR1 on the cell surface reduced K562 cell susceptibility to NK lysis by peripheral blood monuclear cells and a NK cell line. The effect was demonstrable in prolonged (8 hr) cytotoxicity assays and was blocked by pretreatment of target cells with anti-HLA-DR antibody. Treatment of K562 DR transfectant with BFA abrogated the resistance of K562 transfectant to NK-mediated cytolysis. These findings indicate that HLA class II molecules regulate NK cell function and target recognition, and suggest that endogenous peptides presented through MHC molecules are responsible for regulating NK cytolysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778037      PMCID: PMC1384120          DOI: 10.1046/j.1365-2567.1996.483556.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.

Authors:  W J Storkus; J Alexander; J A Payne; J R Dawson; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells.

Authors:  P I Lobo; C E Spencer
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

3.  Target cell expression of MHC antigens is not (always) a turn-off signal to natural killer cells.

Authors:  R Chervenak; R M Wolcott
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

4.  Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen.

Authors:  V Pinet; M S Malnati; E O Long
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

5.  Peptide specificity in the recognition of MHC class I by natural killer cell clones.

Authors:  M S Malnati; M Peruzzi; K C Parker; W E Biddison; E Ciccone; A Moretta; E O Long
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

6.  A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells.

Authors:  P I Lobo; H C Patel
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

7.  NK cell recognition of MHC class I. NK cells are sensitive to peptide-binding groove and surface alpha-helical mutations that affect T cells.

Authors:  Z B Kurago; K D Smith; C T Lutz
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

8.  Natural killer cells: characteristics and regulation of activity.

Authors:  R B Herberman; J Djeu; H D Kay; J R Ortaldo; C Riccardi; G D Bonnard; H T Holden; R Fagnani; A Santoni; P Puccetti
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

9.  Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression.

Authors:  J M Leiden; B A Karpinski; L Gottschalk; J Kornbluth
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

10.  NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules.

Authors:  V Litwin; J Gumperz; P Parham; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

View more
  6 in total

1.  Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Authors:  Douglas B Johnson; Mellissa J Nixon; Yu Wang; Daniel Y Wang; Emily Castellanos; Monica V Estrada; Paula I Ericsson-Gonzalez; Candace H Cote; Roberto Salgado; Violeta Sanchez; Phillip T Dean; Susan R Opalenik; Daniel M Schreeder; David L Rimm; Ju Young Kim; Jennifer Bordeaux; Sherene Loi; Leora Horn; Melinda E Sanders; P Brent Ferrell; Yaomin Xu; Jeffrey A Sosman; Randall S Davis; Justin M Balko
Journal:  JCI Insight       Date:  2018-12-20

2.  Inflammatory infiltration of the upper airway epithelium during Sendai virus infection: involvement of epithelial dendritic cells.

Authors:  A S McWilliam; A M Marsh; P G Holt
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 3.  Extracellular vesicles as emerging targets in cancer: Recent development from bench to bedside.

Authors:  Kerui Wu; Fei Xing; Shih-Ying Wu; Kounosuke Watabe
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-10-18       Impact factor: 10.680

4.  Regulation of NK-Cell Function by HLA Class II.

Authors:  Annika Niehrs; Marcus Altfeld
Journal:  Front Cell Infect Microbiol       Date:  2020-02-18       Impact factor: 5.293

Review 5.  Roles for the FCRL6 Immunoreceptor in Tumor Immunology.

Authors:  Randall S Davis
Journal:  Front Immunol       Date:  2020-10-14       Impact factor: 7.561

6.  The SIRPα-CD47 immune checkpoint in NK cells.

Authors:  Tobias Deuse; Xiaomeng Hu; Lewis L Lanier; Sonja Schrepfer; Sean Agbor-Enoh; Moon K Jang; Malik Alawi; Ceren Saygi; Alessia Gravina; Grigol Tediashvili; Vinh Q Nguyen; Yuan Liu; Hannah Valantine
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.